Top-Rated StocksTop-RatedNASDAQ:DFTX Definium Therapeutics (DFTX) Stock Price, News & Analysis $38.81 +0.13 (+0.34%) As of 09/18/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Definium Therapeutics Stock (NASDAQ:DFTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Definium Therapeutics alerts:Sign Up Key Stats Today's Range$38.10▼$39.0450-Day Range$36.82▼$46.1852-Week Range$8.77▼$49.70Volume3.21 million shsAverage Volume1.95 million shsMarket Capitalization$5.21 billionP/E RatioN/ADividend YieldN/APrice Target$64.88Consensus RatingBuy Company Overview Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York. AI Generated. May Contain Errors. Read More Definium Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreDFTX MarketRank™: Definium Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 314th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingDefinium Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 18 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialDefinium Therapeutics has a consensus price target of $64.88, representing about 67.2% upside from its current price of $38.81.Amount of Analyst CoverageDefinium Therapeutics has been the subject of 16 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Definium Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Definium Therapeutics are expected to grow in the coming year, from ($3.02) to ($1.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Definium Therapeutics is -11.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Definium Therapeutics is -11.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDefinium Therapeutics has a P/B Ratio of 11.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.50% of the float of Definium Therapeutics has been sold short.Short Interest Ratio / Days to CoverDefinium Therapeutics has a short interest ratio ("days to cover") of 5.63.Change versus previous monthShort interest in Definium Therapeutics has recently increased by 9.67%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDefinium Therapeutics does not currently pay a dividend.Dividend GrowthDefinium Therapeutics does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.33 News SentimentDefinium Therapeutics has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 43 news articles for Definium Therapeutics this week, compared to 8 articles on an average week.Search InterestOnly 13 people have searched for DFTX on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat Follows12 people have added Definium Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 71% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Definium Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,887,496.00 in company stock.Percentage Held by Insiders2.40% of the stock of Definium Therapeutics is held by insiders.Percentage Held by Institutions27.91% of the stock of Definium Therapeutics is held by institutions.Read more about Definium Therapeutics' insider trading history. Receive DFTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Definium Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DFTX Stock News HeadlinesAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Definium Therapeutics (DFTX) and enGene Holdings (ENGN)September 17 at 12:12 PM | theglobeandmail.comStifel Nicolaus Reaffirms Their Buy Rating on Definium Therapeutics (DFTX)September 17 at 7:11 AM | theglobeandmail.comA new kind of civil war is coming after election day?Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the political and investment landscape. Whitney Tilson believes tensions may come to a head at midnight on November 4th, the day after the midterm elections, with major implications for your portfolio.September 20 at 1:00 AM | Stansberry Research (Ad)Robert W. Baird Forecasts Strong Price Appreciation for Definium Therapeutics (NASDAQ:DFTX) StockSeptember 17 at 2:15 AM | americanbankingnews.comAnalysts Are Bullish on Top Healthcare Stocks: AdaptHealth (AHCO), Definium Therapeutics (DFTX)September 16, 2026 | theglobeandmail.comStock Traders Purchase Large Volume of Definium Therapeutics Put Options (NASDAQ:DFTX)September 16, 2026 | americanbankingnews.comHC Wainwright Reiterates Buy Rating for Definium Therapeutics (NASDAQ:DFTX)September 16, 2026 | americanbankingnews.comDefinium Therapeutics (NASDAQ:DFTX) Earns "Buy" Rating from Needham & Company LLCSeptember 16, 2026 | americanbankingnews.comSee More Headlines DFTX Stock Analysis - Frequently Asked Questions How have DFTX shares performed this year? Definium Therapeutics' stock was trading at $13.39 on January 1st, 2026. Since then, DFTX shares have increased by 189.8% and is now trading at $38.81. How were Definium Therapeutics' earnings last quarter? Definium Therapeutics, Inc. (NASDAQ:DFTX) released its quarterly earnings results on Thursday, August, 6th. The company reported ($1.44) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by $0.89. Read the conference call transcript. When did Definium Therapeutics' stock split? Definium Therapeutics shares reverse split before market open on Monday, August 29th 2022.The 1-15 reverse split was announced on Monday, August 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Definium Therapeutics' major shareholders? Top institutional investors of Definium Therapeutics include Wellington Management Group LLP (2.20%), AWM Investment Company Inc. (0.58%), Bank of New York Mellon Corp (0.78%) and Seven Fleet Capital Management LP (0.11%). Insiders that own company stock include Robert Barrow, Daniel Karlin, Dan Karlin, Mark Sullivan, Schond L Greenway, Brandi Roberts, Matthew T Wiley, Carrie Liao and David W Gryska. View institutional ownership trends. How do I buy shares of Definium Therapeutics? Shares of DFTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Definium Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Definium Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Tesla (TSLA) and Company Calendar Last Earnings8/06/2026Today9/20/2026TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit9/23/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (14m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 DFTX's financial health is in the Green zone, according to TradeSmith. DFTX has been in this zone for over 14 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:DFTX Previous SymbolNASDAQ:MNMD CIK1813814 Webmindmed.co Phone212 220 6633FaxN/AEmployees40Year Founded2019Price Target and Rating Average Price Target for Definium Therapeutics$64.88 High Price Target$90.00 Low Price Target$25.00 Potential Upside/Downside+67.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage21 Analysts Profitability EPS (Trailing Twelve Months)($3.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$183.79 million Net MarginsN/A Pretax MarginN/A Return on Equity-84.01% Return on Assets-63.66% Debt Debt-to-Equity Ratio0.04 Current Ratio6.95 Quick Ratio6.95 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.36 per share Price / Book11.55Miscellaneous Outstanding Shares134,370,000Free Float131,142,000Market Cap$5.21 billion OptionableOptionable Beta2.23 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:DFTX) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | Sponsored“Elon’s nightmare” could fund your retirementMarc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredYou’ve never seen anything like this beforeFor centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type ...Porter & Company | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredNVDA CEO says it’s a "once-in-a-generation opportunity"NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...Monument Traders Alliance | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Definium Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Definium Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
